Contrast-Induced Nephropathy Prevention

Patient Screening and Assessment

The American Journal of Kidney Diseases recommends using eGFR, not serum creatinine, as the primary screening tool for contrast-induced nephropathy (CIN) risk assessment, because eGFR is a superior indicator of baseline renal function, with a critical threshold of 30 mL/min/1.73 m² 1, 2
For patients with eGFR 30-44 mL/min/1.73 m², contrast administration is permissible but requires mandatory preventive measures, including isotonic saline hydration, use of low-osmolar or iso-osmolar contrast agents, and minimizing contrast volume, as recommended by the American Journal of Kidney Diseases (1A and 1B recommendations) 3, 4, 2
The American Journal of Kidney Diseases suggests that patients with high-risk features, such as pre-existing renal impairment, diabetes mellitus, age >70 years, dehydration, or concomitant nephrotoxic medications, should undergo creatinine testing 3, 4, 1

The American Journal of Kidney Diseases recommends intravenous volume expansion with isotonic sodium chloride or sodium bicarbonate (1A recommendation) and the use of iso-osmolar or low-osmolar contrast agents (1B recommendation) for patients with eGFR 30-60 mL/min/1.73 m² 3, 4, 2
Minimizing contrast volume is also recommended, as well as discontinuing nephrotoxic medications if possible before contrast administration, as suggested by the American Journal of Kidney Diseases 3, 2, 5, 6

Diabetic patients with eGFR <30 mL/min/1.73 m² are at higher risk for CIN, and even small amounts of contrast (30 mL) can precipitate acute kidney failure, according to the American Journal of Kidney Diseases 5, 6
For patients taking metformin, the American College of Cardiology recommends verifying eGFR before contrast administration and withholding metformin for 48 hours after the procedure for patients with eGFR 30-60 mL/min/1.73 m² 1

Re-evaluating kidney function (serum creatinine) within 48-96 hours after contrast administration is recommended for patients with baseline eGFR <60 mL/min/1.73 m² or other high-risk features, as suggested by the American Journal of Kidney Diseases 1